Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Change in Accured Expenses (2024 - 2025)

Prelude Therapeutics (PRLD) has disclosed Change in Accured Expenses for 2 consecutive years, with -$515000.0 as the latest value for Q4 2025.

  • Quarterly Change in Accured Expenses fell 132.87% to -$515000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.0 million through Dec 2025, down 268.81% year-over-year, with the annual reading at -$3.0 million for FY2025, 268.81% down from the prior year.
  • Change in Accured Expenses hit -$515000.0 in Q4 2025 for Prelude Therapeutics, down from -$367000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.1 million in Q3 2024 to a low of -$5.7 million in Q1 2024.